Patent Tracker

Applications for patents related to psychedelics have boomed in recent years. Nonprofits, pharmaceutical companies, startups, and academic institutions are all jockeying to patent specific psychedelic compounds and formulations. To help keep tabs on the status of patent applications as they wind their way through the U.S. Patent and Trademark’s review process, BCSP has created a patent tracker that uses publicly available data gathered by Psychedelic Alpha, an independent community working in the psychedelic space. Read more about the history and process of psychedelic patents here.

667 Patents

DMT

Title

Composition for transdermal delivery of cationic active agents

Subject Matter

Transdermal patch with composition for transdermal delivery of at least one cationic active agent, including indole compounds such as N,N-DMT

DMT

Title

Compounds for increasing neural plasticity

Subject Matter

Methods for increasing neural plasticity by contacting a neuronal cell with a non-hallucinogenic analog of a psychedelic compound, including analogs of DMT

DMT

Title

Compositions containing toad secretion compounds

Subject Matter

Disclosed are compositions containing two purified toad secretion tryptamines chosen from the following 5-MeO-DMT, 5-MeO-NMT, 5-Methoxytryptamine, bufobutanoic Acid, bufobutarginine, bufoserotonin A, bufoserotonin B, bufoserotonin C, bufotenidine, bufotenin, bufotenin Oxide, bufotenine-O-Sulphate, bufoviridine, dET, dMT, n-Acetylserotonin, n’-Formylserotonin, n-Methylserotonin, o-Methylbufoviridine, serotonin, tryptamine, and bufopyramide or the salts of these toad secretion tryptamines. The disclosure also relates to formulations, including pharmaceutical formulations, of such a composition and an excipient. Pharmaceutical formulation further containing a therapeutically effective amount of a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, or a purified terpene a disclosed. Also disclosed are methods of regulating the activity of a neurotransmitter receptor and methods of treating a psychological disorder, a compulsive disorder, or a depressive disorder.

DMT

Title

Method of treating mucosal inflammation

Subject Matter

Methods of treating mucosal inflammation in the gastrointestinal tract, by administering 5-HT7 receptor antagonist, including N,N-DMT

DMT

Title

Method for extracting target alkaloid using an ionic liquid as extracting solvent

Subject Matter

Methods for extracting a target alkaloid from a mixture of species, by using an ionic liquid as an extracting solvent, including for N,N-DMT and 5-MeO-DMT

DMT

Title

Novel rodent control agents and uses thereof

Subject Matter

Methods for controlling rodents by contacting the rodents with a compound which is a ligand for an olfactory TAAR receptor, including 5-MeO-DMT

DMT

Title

Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof

Subject Matter

Pharmaceutical compositions of a AMPK activator and a serotonergic agent, the serotonergic agent including N,N-DMT and 5-MeO-DMT

DMT

Title

Novel composition for treating metabolic syndrome and other conditions

Subject Matter

Compositions of an oxidative phosphorylation inhibitor, ionophore, or AMPK activator; an anti-inflammatory agent; and a serotonergic agent, including N,N-DMT and 5-MeO-DMT

Psilocybin

Title

Fungal compound compositions and methods for modulating inflammation

Subject Matter

Described herein are fungal compound compositions and methods for treating, prophylaxis of, or ameliorating symptoms of one or more adverse reactions triggered by an infectious disease or condition that increases an anti-inflammatory response in a subject with such compositions. In one aspect, the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof, optionally combined with one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum), or combinations thereof, optionally one or more adversive compounds, optionally one or more monoamine oxidase inhibitor (MAOI) compounds, and optionally one or more pharmaceutically acceptable excipients.

Psilocybin

Title

Psilocybin and psilocin conjugates for treatment of mental illnesses

Subject Matter

New psilocybin and psilocin conjugates and their soluble salts with synergistic or additive therapeutic agents and stable formulations thereof, as well as their medical applications. The synergistic or additive conjugates may be used as drugs or prodrugs for treating various mental illness conditions related to the modulation or biased modulation of serotonin and related receptors, including but not limited to neurodegenerative disorders, depression, anxiety, obsessive compulsive disorder (OCD), cluster headaches, neuropathic pain and addiction.

Page 1 of 67

Filters
Sort